The aim of this pilot study is to explore the utility of a new imaging technique, called Field Cycling Imaging (FCI), in postoperative low grade gliomas.
The main question it aims to answer is if FCI can differentiate subtypes of low grade gliomas. Participants will have one FCI scan.
Who can participate
Age range
16 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with post operative low-grade glioma.
* Capacity to give informed consent.
* Capacity to co-operate with the scanning procedures and duration.
* Age 16 and above.
* Participants who can pass through a 50 cm-diameter circular hoop to ensure they will be able to fit inside the scanner.
* Participants who meet the safety criteria for undergoing an MRI scan.
* Participants must be mobile enough to be positioned onto the FCI scanner couch.
Exclusion Criteria:
* MRI-incompatible conditions, as detected in the MRI safety screening form.
* Restrictions to mobility that would prevent the correct positioning in the scanner by trained research radiographer (e.g., severe kyphosis).
* Participants who are unable to give fully informed consent.
* Women who are pregnant.
* Participants who are unable to understand or communicate in English.
* Patients who suffer from claustrophobia.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial used a technology called Field Cycling Imaging to try to tell apart sub-types of low-grade glioma after surgery — could my doctor explain whether knowing my specific sub-type in this level of detail would actually change my treatment plan?
2Since this trial is already completed and wasn't testing a treatment but rather an imaging method, is there any way I could benefit from or access this FCI imaging technology, or are the results still being analyzed and not yet available in clinical practice?
3Low-grade gliomas have several sub-types that behave very differently — can my doctor walk me through which sub-type I have and whether standard imaging has already given us enough information to guide my care?
4Because this was a non-treatment imaging study with no listed phase, it was focused on gathering data rather than testing safety or benefit of a therapy — does my doctor think the findings from this kind of research are relevant to decisions I need to make now about my post-operative follow-up?
5Are there other ongoing trials or established approaches for monitoring low-grade glioma after surgery that my doctor would consider a better fit for my situation right now, given that this particular study has already closed?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Differentiation of sub-types of low grade glioma assessed by Field Cycling Imaging (FCI) T1 dispersion profiles